Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary ...

Vaxart secures major Dynavax deal, extending cash runway to 2027. Get Q3 earnings insights, clinical progress, and outlook on innovative oral vaccines.

AIRJ Expands Strategic Partnerships and Advances Productization of AirJoule™ Systems Ahead of Commercial Deployments in 2026 ...

PolyPid Ltd. (NASDAQ: PYPD) Q3 2025 Earnings Call Transcript November 12, 2025 PolyPid Ltd. beats earnings expectations.

Q3 2025 Earnings Call November 13, 2025 5:00 PM ESTCompany ParticipantsKelly Goodman - Interim CEO & Corporate ...

Learn how the European Union’s Corporate Sustainability Reporting Directive (CSRD) is designed to enhance the transparency of ...

Security leaders are under increasing pressure to prove that their defenses actually work. Board members and stakeholders want to see measurable progress, yet most metrics available to CISOs today don ...

Operator: Good morning, everyone. And welcome to the Abeona Therapeutics third quarter 2025 conference call. At this time, ...

Aftermarket antenna and enterprise custom products continue to be negatively affected by channel inventory overhang, largely ...

Research and development expense in fiscal Q3 2025 -- $4.5 million versus $4.9 million in fiscal Q3 2024. Net loss -- $5.9 ...

Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relationsAdvanced mu ...

The federal government has reiterated that Nigeria's 'Decade of Gas' programme spanning 2021-2030 has so far unlocked about 215 strategic upstream and midstream gas projects worth over $8 billion ...